Segments - Operations and Assets Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 01, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Total revenues	$ 309,893	$ 442,408	$ 639,111	$ 987,573
Operating income (loss)	(10,739)	5,571	(83,164)	44,008
Depreciation and amortization	27,995	20,573	55,809	40,561
Loss from investment in investees	(268)	(67)	(316)	(110)
Assets	2,369,602		2,369,602			$ 2,399,715
Goodwill	578,845		578,845		$ 710,408	520,601
United States
Segment Reporting Information [Line Items]
Total revenues	193,105	402,291	484,913	915,163
Ireland
Segment Reporting Information [Line Items]
Total revenues	89,177	12,088	97,638	19,218
Chile
Segment Reporting Information [Line Items]
Total revenues	15,804	18,657	32,143	32,809
Spain
Segment Reporting Information [Line Items]
Total revenues	5,696	5,437	12,805	11,356
Israel
Segment Reporting Information [Line Items]
Total revenues	1,854	724	3,412	3,235
Mexico
Segment Reporting Information [Line Items]
Total revenues	4,055	3,039	7,805	5,457
Other
Segment Reporting Information [Line Items]
Total revenues	202	172	395	335
Corporate
Segment Reporting Information [Line Items]
Operating income (loss)	(8,631)	(10,719)	(19,399)	(20,138)
Depreciation and amortization	0	0	0	0
Loss from investment in investees	0	0	0	0
Assets	267,379		267,379			46,672
Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)	55,435	(13,710)	37,327	(32,868)
Depreciation and amortization	17,840	7,007	33,242	14,420
Loss from investment in investees	(268)	(67)	(316)	(110)
Assets	1,354,058		1,354,058			1,114,460
Goodwill	295,820		295,820			237,576
Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)	(57,543)	30,000	(101,092)	97,014
Depreciation and amortization	10,155	13,566	22,567	26,141
Loss from investment in investees	0	0	0	0
Assets	748,165		748,165			1,238,583
Goodwill	283,025		283,025			$ 283,025
Services
Segment Reporting Information [Line Items]
Total revenues	186,804	397,197	473,402	904,149
Services | Corporate
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Services | Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Services | Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	186,804	397,197	473,402	904,149
Products
Segment Reporting Information [Line Items]
Total revenues	35,892	35,663	72,550	69,608
Products | Corporate
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Products | Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	35,892	35,663	72,550	69,608
Products | Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Transfer of intellectual property and other
Segment Reporting Information [Line Items]
Total revenues	87,197	9,548	93,159	13,816
Transfer of intellectual property and other | Corporate
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Transfer of intellectual property and other | Pharmaceutical | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	87,197	9,548	93,159	13,816
Transfer of intellectual property and other | Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Total revenues	$ 0	$ 0	$ 0	$ 0